Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: A Randomized Controlled Trial

Obstetrics and Gynecology

Volumn 121, Issue 5, 2013, Pages 943-950

  Wong, Alice W Y ^a   Chan, Symphorosa S C ^a   Yeo, Winnie ^a   Yu, Mei Yung ^a   Tam, Wing Hung ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

LEVONORGESTREL; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; ENDOMETRIUM TUMOR; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTEROSCOPY; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBMUCOSAL FIBROID; TRANSVAGINAL ECHOGRAPHY; UTERUS CAVITY;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; ENDOMETRIAL HYPERPLASIA; FEMALE; HUMANS; LEVONORGESTREL; MIDDLE AGED; TAMOXIFEN;

EID: 84879104011     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31828bf80c     Document Type: Article

References (29)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
2. Neven P, De Muylder X, Van Belle Y, Van Hooff I, Vanderick G. Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet 1998; 351: 36.
3. Ozsener S, Ozaran A, Itil I, Dikmen Y. Endometrial pathology of 104 postmenopausal breast cancer patients treated with tamoxifen. Eur J Gynaecol Oncol 1998; 19: 580-3.
4. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994; 343: 448-52.
5. Varma R Soneja H, Bhatia K, Ganesan R Rollason T, Clark TJ, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia - a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 2008; 139: 169-75.
6. Wan YL, Holland C. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review. Climacteric 2011; 14: 622-32.
7. Chan SS, Tam WH, Yeo W, Yu MM, Ng DP, Wong AW, et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG 2007; 114: 1510-5.
8. Chin J, Konje JC, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. The Cochrane Database of Systematic Reviews 2009; 4:CD007245. DOI: 10.1002/14651858.CD007245.pub2.
9. Gardner FJ, Konje JC, Bell SC, Abrams KR, Brown LJ, Taylor DJ, et al. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial. Gynecol Oncol 2009; 114: 452-6.
10. Tam WH, Yuen PM, Shan Ng DP, Leung PL, Lok IH, Rogers MS. Health status function after treatment with thermal balloon endometrial ablation and levonorgestrel intrauterine system for idiopathic menorrhagia: a randomized study. Gynecol Obstet Invest 2006; 62: 84-8.
11. Mantel N, Mocarelli P, Marocchi A, Brambilla P, Baretta R. Stratified analysis of multivariate clinical data: application of a Mantel-Haenszel approach. Statist Med 1983; 2: 259-66.
12. Begg MD, Panageas KS. Interval estimation of the common odds ratio from k(232) tables under cluster sampling. Statist Med 1999; 18: 1087-100.
13. Garuti G, Grossi F, Cellani F, Centinaio G, Colonnelli M, Luerti M. Hysteroscopic assessment of menopausal breast-cancer patients taking tamoxifen; there is a bias from the mode of endometrial sampling in estimating endometrial morbidity? Breast Cancer Res Treat 2002; 72: 245-53.
14. Dibi RP, Zettler CG, Pessini SA, Ayub AV, de Almeida SB, da Silveira GP. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer. Menopause 2009; 16: 293-300.
15. Zarbo G, Caruso G, Zammitti M, Caruso S, Zarbo R. The effects of tamoxifen therapy on the endometrium. Eur J Gynaecol Oncol 2000; 21: 86-8.
16. Pakarinen P, Toivonen J, Luukkainen T. Therapeutic use of the LNG IUS, and counseling. Semin Reprod Med 2001; 19: 365-72.
17. Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intrauterine systems. Semin Reprod Med 2001; 19: 355-63.
18. Prossnitz ER, Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol 2011; 7: 715-26.
19. Ignatov T, Eggemann H, Semczuk A, Smith B, Bischoff J, Roessner A, et al. Role of GPR30 in endometrial pathology after tamoxifen for breast cancer. Am J Obstet Gynecol 2010; 203: 595 e9-16.
20. Turbiner J, Moreno-Bueno G, Dahiya S, Sanchez-Estevez C, Hardisson D, Prat J, et al. Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen. Mod Pathol 2008; 21: 925-36.
21. Aupperlee M, Kariagina A, Osuch J, Haslam SZ. Progestins and breast cancer. Breast Dis 2005; 24: 37-57.
22. Raudaskoski T, Tapanainen J, Tomas E, Luotola H, Pekonen F, Ronni-Sivula H, et al. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG 2002; 109: 136-44.
23. Trinh XB, Tjalma WA, Makar AP, Buytaert G, Weyler J, van Dam PA. Use of the levonorgestrel-releasing intrauter-ine system in breast cancer patients. Fertil Steril 2008; 90: 17-22.
24. Backman T, Rauramo I, Jaakkola K, Inki P, Vaahtera K, Launonen A, et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 2005; 106: 813-7.
25. Morales L, Timmerman D, Neven P, Konstantinovic ML, Carbonez A, Van Huffel S, et al. Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. Ann Oncol 2005; 16: 70-4.
26. Bertelli G, Hall E, Ireland E, Snowdon CF, Jassem J, Drosik K, et al. Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES) - a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen. Ann Oncol 2010; 21: 498-505.
27. Josefsson ML, Leinster SJ. Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy. Breast 2010; 19: 76-83.
28. van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011; 377: 321-31.
29. Ciatto S, Cecchini S, Gervasi G, Landini A, Zappa M, Crocetti E. Surveillance for endometrial cancer with transvaginal ultrasonography of breast cancer patients under tamoxifen treatment. Br J Cancer 2003; 88: 1175-9.